TNF阻害薬に効果不十分または不耐な活動性乾癬性 関節炎患者におけるビメキズマブ: 無作為化二重盲検 プラセボ対照フェーズ3試験 (BE COMPLETE)
Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0
This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.
Keywords:
